Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (4577)	9/4/2001 7:09:17 AM
From: OldAIMGuy	Read Replies (1) \| Respond to of 52153

Another player in the making..... jsonline.com Blood from stem cell research..... Best regards, Tom

To: OldAIMGuy who wrote (4577)	9/7/2001 2:50:48 PM
From: OldAIMGuy	Respond to of 52153

BPUR vs NFLD (continued) I received this note from an SI lurker regarding my previous post........ "In your comparison of the two companies, you note the phrase, "Hemopure should not be used in patients with....... a known hypersensitivity to bovine hemoglobin..." That doesn't necessarily mean any such sensitivity has been identified. It's a standard cautionary statement found in the package insert of every drug. Don't use this drug in individuals who have previously had problems with it. It's pretty much a legal "duh" statement. It's even found in safety information for oxygen." Hope this helps your evaluation. Best regards, Tom